Multiple Sourcing Framework Contracts to Speed up the Development of and Access to Innovative Medical Countermeasures: Next-Generation Influenza Vaccines

eukaryotic or bacterial cell culture, in plants or via in vitro transcription), could support products utilising novel administration routes (e.g. nasal, oral or through microneedle patches), confer mucosal immunity, target potentially pandemic influenza A viruses or could be rapidly adapted to pand

emic influenza A viruses, which are protective across influenza subtypes or across alpha-influenza viruses, and/or possess intrinsic immunogenicity without the addition of adjuvants. The call will be implemented via a competitive developmen